Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2

    Brett King, Manabu Ohyama, Maryanne M. Senna … Bianca Maria Piraccini
    Studysummary At Week-104 of the BRAVE-AA2 trial, this study found that 90.2% of severe alopecia areata patients who continued on baricitinib 4mg maintained hair regrowth, whereas 45.2% of those who reduced their dosage to 2mg experienced a loss of treatment benefit.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →